Clinical efficacy of FOLFOX regimen in the treatment of locally advanced or metastatic gastric cancer

Objective To study the clinical efficacy of FOLFOX regimen, oxaliplatin (L-OHP) combined with fluorouracil (5-Fu) and calcium folinate (CF), in the treatment of locally advanced or metastatic gastric cancer. Methods All the patients were treated with L-OHP 85 mg/m2 i.v. 2 h and CF 200 mg/m2 i.v. 2 h, followed by 5-Fu 400 mg/m2 i.v. on day 1, and then 5-Fu 1 500 mg/m2 c.i.v. 46 h, every 2 weeks, for four cycles. Results Of the 23 patients, one case (4.3%) reached complete remission (CR), 8 cases (34.8%) reached partial remission (PR), 10 cases (43.5%) reached stable disease (SD), and 4 cases (17.4%) reached progressive disease (PD). The overall response rate was 39.1%. The median TTP and median survival time was 5.4 months and 10.6 months, respectively. The grade 3 and 4 adverse reactions included leukopenia in 3 cases (13.0%), anaemia in 1 case (4.3%), nausea and vomiting in 1 case (4.3%), and neurotoxicity in 2 cases (8.7%). Conclusion The FOLFOX regimen is effective for treating locally advanced or metastatic gastric cancer, with no severe adverse reactions and good patient tolerance.